Sleep Disorders

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending December 13, 2025. [WATCH TIME: 4 minutes]

The president and CEO at Project Sleep discussed how inaccurate media portrayals of narcolepsy can contribute to stigma, misunderstanding of symptoms, and delays in clinical diagnosis. [WATCH TIME: 5 minutes]

TRN-257, a treatment in development for adults with narcolepsy and idiopathic hypersomnia, is designed to reduce daily sodium exposure relative to existing higher-sodium therapies.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Vaishal Shah, MD, MPH, FAASM, FAAP, center director of the Sleep Disorders Center at Cleveland Clinic, spoke on the changes in how obstructive sleep apnea is treated, moving away from CPAP to more novel approaches.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending November 15, 2025. [WATCH TIME: 4 minutes]

Centessa Pharmaceuticals reveals promising early-stage results for its orexin receptor 2 agonists, ORX750 and ORX142, targeting neurologic sleep disorders.

New trial results reveal alixorexton's significant efficacy in treating narcolepsy type 2, marking a potential breakthrough in sleep medicine.

Here's some of what is coming soon to NeurologyLive® this week.

Experts discussed the benefits and challenges of once-nightly versus twice-nightly oxybate regimens for narcolepsy, emphasizing adherence, patient lifestyle, and comorbidity considerations. [WATCH TIME: 5 minutes]

Experts discussed REFRESH study data highlighting oxybates’ tolerability, effectiveness, and potential to reduce stimulant burden in patients with narcolepsy. [WATCH TIME: 5 minutes]

Experts discussed the prevalence of comorbidities in narcolepsy and how targeted therapies, particularly oxybate, can improve both sleep quality and associated psychiatric symptoms. [WATCH TIME: 9 minutes]

Experts discussed findings, presented at the 2025 World Sleep Congress, showing how once-nightly oxybate improved adherence, quality of life, and partner burden in patients with narcolepsy. [WATCH TIME: 9 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 10, 2025.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 3, 2025.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 26, 2025.

Dionne Morgan, MD, a sleep medicine physician at Baptist Health Miami Cardiac & Vascular Institute, provided commentary on World Narcolepsy Day, highlighting challenges in diagnosis and treatment, evolution in therapeutics, and combating comorbidities.

New research highlights daridorexant's effectiveness in improving sleep for women experiencing insomnia during menopause, showcasing significant benefits in sleep quality.

Neurology News Network. for the week ending September 13, 2025. [WATCH TIME: 4 minutes]